From 1 December 2024, Pharmac is also removing the renewal criteria for methylphenidate, dexamfetamine and modafinil, medicines used to treat ADHD and narcolepsy. This means that once an initial ...

Advocacy group Aroreretini Aotearoa, says the changes will improve productivity for the ADHD community, by almost 57-million-dollars. Chief medical officer David Hughes says it will streamline ...

People with some types of thyroid and liver cancer are getting free access to a targeted treatment for the first time, with ...

The drug buying agency will also remove the renewal criteria for people with ADHD and narcolepsy.

Pharmac has announced it'll fund new stimulant medicine lisdexamfetamine from December. The medicine -- branded as Vyvanse -- is taken once a day. Chief medical officer, David Hughes, says it's a ...

Deputy Health and Disability Commissioner Rose Wall has today released a report finding a registered midwife breached the ...

Patients want National to take note of a report on blood cancer medicines and remember its pre-election promise that they ...

Christopher Luxon announced details of the Government's $604 million boost to the budget of New Zealand’s drug-buying agency ...

She says having another option out there means we're not so dependent on patches anymore, which is good news for a lot of ...

Associate Health Minister with responsibility for Pharmac David Seymour is pleased to see further increased availability of medicines for Kiwis ...

Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...